Multifunctional Spiky Topological Nanocapsules for the Discrimination and Differential Inhibition of Inflammation and Cancer.
Animals
Apoptosis
Carcinoma, Hepatocellular
/ drug therapy
Cell Movement
Cell Proliferation
Drug Liberation
Female
Humans
Inflammation
/ drug therapy
Liver Neoplasms
/ drug therapy
Mice
Mice, Inbred BALB C
Mice, Nude
MicroRNAs
/ genetics
Monocarboxylic Acid Transporters
/ antagonists & inhibitors
Nanocapsules
/ administration & dosage
Pyrimidinones
/ chemistry
Symporters
/ antagonists & inhibitors
Thiophenes
/ chemistry
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
differential inhibition
discrimination
inflammation and cancer
spiky topological nanocapsules
time-resolved dual detection
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
09 Jun 2021
09 Jun 2021
Historique:
pubmed:
29
5
2021
medline:
29
7
2021
entrez:
28
5
2021
Statut:
ppublish
Résumé
Accurate discrimination of inflammations and cancers as well as differential inhibition of cancers are significant for early diagnoses and timely treatments. Nanoparticles have become new modalities for diagnosis and therapy. However, they are still challenged by the efficient delivery of multiple reagents into living cells, discriminating multisignals without any interference, and differential treatments of different diseases. Here, multifunctional spiky topological nanocapsules (STNs) are prepared for the discrimination and differential inhibition of inflammation and cancer. With unique spiky hollow architectures, STNs' advantages including excellent loading capacity, enhanced cellular uptake, DNAs' protection against degradation, target-controlled drug release, and efficient endo-/lysosome escape are demonstrated. Therefore, sequential detection of inflammation-related miR-155 (by external modified hairpin DNAs) and the cancer target of monocarboxylate transporter 1 (MCT1) (by internal loaded pH-sensitive carbon dots and MCT1 inhibitor-AZD3965) are achieved. Furthermore, the release of AZD3965 from the cavities of STNs is controlled by the miR-155 amount (first target). Therefore, the released drug of AZD3965 realizes the stage-dependent differential treatment of diseases via cellular acidosis induced by MCT1 inhibition. Via in vivo evaluations of normal, inflammatory, and liver cancer cells/mice, as well as the efficient inhibition of tumor growth, the possibility of STN-based discrimination and differential treatment is confirmed. This would encourage new strategies for multidiagnosis and differential treatment of early-stage cancer.
Identifiants
pubmed: 34048646
doi: 10.1021/acsami.1c04737
doi:
Substances chimiques
AZD3965
0
MIRN155 microRNA, human
0
MicroRNAs
0
Monocarboxylic Acid Transporters
0
Nanocapsules
0
Pyrimidinones
0
Symporters
0
Thiophenes
0
monocarboxylate transport protein 1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM